SON Formula®

The most nutritious and the most health-preserving in comparison
to any dietary protein, protein supplement or amino acid formula.

SON Formula® is a medical food, 100% made in the U.S.A. Medical foods are required by statute to be administered under the supervision of a physician, but there is no requirement for a prescription.

Disclaimer:
The following information is intended for medical doctors with advanced knowledge in human nutrition.

Indications and Usage

Medical Food Name

SON Formula® (map master amino acid pattern®).

Qualitative and Quantitative Composition

SON Formula® is supplied in bottles containing 120 uncoated white tablets of 1,000 mg each. SON Formula contains only the active ingredient MAP Master Amino Acid Pattern® and does not contain any inactive ingredient or excipient.

 

Clinical Studies

 

In 1992, the International Nutrition Research Center, a leading U.S.A. research institute, leader in the field of human nutrition, led by Prof. Dr. Maurizio Lucà-Moretti, published four comparative, double-blind, triple, and quintuple-crossover clinical Net Nitrogen Utilization (NNU) studies conducted in human subjects, while ingesting SON Formula® (map master amino acid pattern®), as a total substitute for dietary proteins1-4.

The scientific evidence obtained from the previously described clinical studies1-4 has shown and confirmed the discovery of SON Formula® (map master amino acid pattern®), considered one of the most important nutritional scientific breakthroughs of the 20th century.

Since 1992, have been published forty-five clinical studies conducted in human subjects1-45 while ingesting SON Formula® as a partial or total substitute for dietary protein.

Considering the scientific evidence previously described, it can be concluded that this is the highest number of scientific publications of clinical studies conducted in human subjects1-45 ever published for any dietary protein, protein supplement, or amino acid formula.

In recognition to the originality of SON Formula® (map master amino acid pattern®) and its unprecedented nutritional effectiveness, numerous patents have been granted by the following 30 nations: United States of America, Canada, Japan, Austria, Belgium, Bulgaria, Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain and Sweden.

Considering the scientific evidence previously described, it can be concluded that the discovery of SON Formula® (map master amino acid pattern®) has been granted with the highest number of patents from the highest number of nations, in recognition of its originality and unprecedented nutritional effectiveness, in comparison to any dietary protein, protein supplement, or amino acid formula.

SON Formula® Uniqueness

The scientific evidence obtained from forty-five published comparative clinical studies, conducted in human subjects1-45 has shown and confirmed that the use of SON Formula® (map master amino acid pattern®), based on its six unique characteristics*, is indicated as a medical food, under medical supervision, as a partial and/or total substitute for dietary proteins as:

  • the most nutritious and the most health-preserving

in comparison to any dietary protein, protein supplement, or amino acid formula.

The Six Unique Characteristics of SON Formula®

1. SON Formula® provides a unique, unprecedented, constant Body Protein Synthesis (BPS = 99% NNU/23 min), namely the highest in comparison to any dietary protein, protein supplement, or amino acid formula.

Comparative clinical Net Nitrogen Utilization (NNU) studies conducted in human subjects1-4 have shown and confirmed that the use of SON Formula® provides an unprecedented, unique, constant BPS = 99% NNU/23 min*. On the contrary, dietary proteins provide a variable BPS of 16-32% NNU/180-360 min. That is, a BPS 24 to 96 times lower compared to that of SON Formula®. As a result, it can be concluded that SON Formula® provides a BPS that is 24 to 96 times higher in comparison to that provided by any dietary protein, protein supplement, or amino acid formula.

Bar graph comparing BPS of SON Formula and dietary proteins/protein supplements.

*To illustrate: the Body Protein Synthesis (BPS = %NNU/min), is the scientific index that defines a specific dietary protein nutritional value. Therefore, the higher a dietary protein BPS, the higher its nutritional value, and vice versa.

Considering the scientific evidence1-4 previously described, it can be concluded that SON Formula® is the most nutritious and the most health-preserving in comparison to any dietary protein, protein supplement, or amino acid formula.

2. SON Formula® requires less than 23 minutes to be digested. That is, the shortest digestion time ever required in comparison to any dietary protein, protein supplement, or amino acid formula.

Comparative clinical studies conducted in human subjects1-4 have shown that SON Formula® requires less than 23 minutes to be digested. On the contrary, dietary proteins require a digestion time of 180 to 360 minutes (3 to 6 hours). That is, a digestion time 6 to 12 times longer in comparison to SON Formula®. As a result, it can be concluded that SON Formula® requires a digestion time 6 to 12 times shorter in comparison to any dietary protein, protein supplement, or amino acid formula.

Clocks showing digestion times for SON Formula and dietary proteins.

Considering the scientific evidence1-4 previously described, it can be concluded and confirmed that the use of SON Formula® is the most nutritious and the most health-preserving in comparison to any dietary protein, protein supplement, or amino acid formula.

3. The use of SON Formula® releases only 1% nitrogen catabolites, namely, metabolic toxic waste. That is, the lowest amount of nitrogen catabolites ever released, in comparison to any dietary protein, protein supplement, or amino acid formula.

Comparative clinical studies conducted in human subjects1-4 have shown that the use of SON Formula® releases only 1% nitrogen catabolites. In contrast, dietary proteins, during digestion, release 68 to 84% nitrogen catabolites. That is, 67 to 83 times more metabolic toxic waste, to be catabolized through the hepatic and renal function. As a result, it can be concluded that the use of SON Formula® releases 67 to 83 times less nitrogen catabolites, meaning metabolic toxic waste, in comparison to any dietary protein, protein supplement, or amino acid formula.  

Graph showing nitrogen catabolites released by SON Formula and dietary proteins.

Considering the scientific evidence1-4 previously described, it can be concluded and confirmed that the use of SON Formula® is the safest and therefore the most health-preserving in comparison to any dietary protein, protein supplement, or amino acid formula.

4. The use of SON Formula® provides only 0.04 kcal/g. That is, the lowest amount of kcal/g ever provided in comparison to any dietary protein, protein supplement, or amino acid formula.

Comparative clinical studies conducted in human subjects1-4 have shown that the use of SON Formula® provides only 0.04 kcal/g. In contrast, dietary proteins provide 4 kcal/g. That is, 99 times more kilocalories per gram in comparison to SON Formula®. As a result, it can be concluded that SON Formula® provides 99 times fewer kilocalories per gram in comparison to any dietary protein, protein supplement, or amino acid formula.

Considering the scientific evidence1-4 previously described, it can be concluded and confirmed that the use of SON Formula® is the safest and therefore the most health-preserving in comparison to any dietary protein, protein supplement, or amino acid formula.

5. SON Formula®, in contrast to any dietary protein or protein supplement, contains no protein, lipid, carbohydrate, vitamin, mineral, trace element, or excipient.

SON Formula® contains only the active ingredient MAP Master Amino Acid Pattern®, and it does not provide any inactive ingredient or excipient. As a result, the use of SON Formula® in substitution for dietary proteins allows for an easier and more efficient clinical nutrition management by limiting the intake of any unwanted macronutrient and/or micronutrient.

Considering the scientific evidence1-4 previously described, it can be concluded and confirmed that the use of SON Formula® allows for an easier, safer, and more efficient clinical nutrition management, to prevent or limit the intake of any non-required macronutrient or micronutrient.

6. The sixth and last unique characteristic of SON Formula® originates from the cumulative effects of its previously described five unique characteristics. Therefore, the use of SON Formula®, in substitution for dietary proteins, protein supplements, or amino acid formulas, can significantly reduce renal, hepatic, pancreatic, digestive, cardiovascular, and/or respiratory load, in comparison to any dietary protein, protein supplement, or amino acid formula.

CONCLUSIONS

The scientific evidence obtained from the publication of forty-five comparative clinical studies, conducted in human subjects, while ingesting SON Formula®, as a partial or total substitute for dietary proteins, has shown and confirmed that the use of SON Formula® is:

  • the most nutritious and the most health-preserving

in comparison to any dietary protein, protein supplement, or amino acid formula.

SON Formula® Mode of Action (MoA)

Based on the previously described scientific evidence1-45, the use of SON Formula® (map master amino acid pattern®) due to its six unique characteristics, is indicated, as medical food, under medical supervision, as a partial and/or total substitute for dietary proteins, as the most nutritious and the most health-preserving, compared to any dietary protein, protein supplement, or amino acid formula:

  1. To prevent a Negative Body's Nitrogen Balance.
  2. To achieve and/or maintain a Body's Nitrogen Balance in Equilibrium.
  3. To achieve and/or maintain a Body's Positive Nitrogen Balance.
  4. To reach the required Body's Cellular Turnover, as well as the hormones and enzymes production necessary to optimize the quality and expectancy of life.

 

Indication and Usage

The use of SON Formula® (map master amino acid pattern®) is indicated, as medical food, under medical supervision, as the most nutritious and the most health-preserving, partial or total substitute for dietary proteins, in comparison to any dietary protein, protein supplement, or amino acid formula, during:

AIDS
Alcoholism (delirium tremens)
Alzheimer
Anorexia
Anemia
Bariatric surgery
Breastfeeding
Bulimia
Burns
Cachexia
Cancer
Chronic or acute renal insufficiency
Chronic kidney disease (CKD)

Crohn's disease
Degenerative diseases
Diabetes I or II
Gastrointestinal disorders
Geriatric nutrition
Hepatic failure
Immunodeficiency
Infertility
Malabsorption
Malnutrition
Obesity
Osteoporosis
Overweight
Parkinson’s disease

Pediatric nutrition
Physical therapy
Pre-surgery and/or post-surgery
Preeclampsia
Pregnancy
Proteinuria
Renal failure
Recovery from sport injuries
Tuberculosis
Uremia
Vegetarianism
Wasting syndrome

Posology and Method of Administration (under medical supervision)

SON Formula® recommended dosage: to be determined by a physician.

Comparative clinical studies conducted in healthy human subjects1-4 have shown that a daily dosage of 200 mg of SON Formula® per lb of body’s ideal weight is adequate, as a total substitute for dietary proteins, to maintain the Body’s Nitrogen Balance in Equilibrium.

For example, to calculate the dosage of SON Formula® necessary to substitute 10 g of high biological value dietary proteins, proceed as follows:

1. SON Formula® dosage = (dietary proteins x 0.4) g

2. SON Formula® dosage = (10 x 0.4) g

3. SON Formula® dosage = 4 g

Therefore, 4 tablets (4 g) of SON Formula® provide a Body’s Protein Synthesis (BPS) equivalent to at least that provided by 10 g of dietary proteins with the highest biological value.

Contraindications

None known.

Adverse Reactions

None known.

Drugs Interaction

None known.

Precautions

SON Formula® should be stored in a dry place at 68-77°F (20-25°C).

How Supplied

SON Formula® is available in bottles containing 120 tablets of 1,000mg each, for oral administration.

SON Formula® and MAP Master Amino Acid Pattern® Related Scientific Publications

  1. Lucà-Moretti M. Comparative study of subjects’ Net Nitrogen Utilization (NNU) while receiving SON, a nutritional amino acid formula, or high biological value egg protein, or egg protein amino acid formula. JIMHA; 1:33-42, 1992.
  2. Lucà-Moretti M. Comparative study of subjects’ Net Nitrogen Utilization (NNU) while receiving SON, or egg protein or its protein amino acid formula. Advances in Therapy; 5:280-89, 1992.
  3. Lucà-Moretti M. Comparative study of subjects’ Net Nitrogen Utilization (NNU) while receiving bovine milk or soybean flour with or without SON nutrification. JIMHA; 1:43-54, 1992.
  4. Lucà-Moretti M. Comparative study of subjects’ Net Nitrogen Utilization (NNU) while receiving bovine milk or soybean flour with or without SON nutrification. Advances in Therapy; 5:290-301, 1992.
  5. Lucà-Moretti M., Grandi, A. The Malnutrition Treatment and Prevention Project. JIMHA; 2:20-26, 1993.
  6. Lucà-Moretti M., Grandi, A. Comparative Study of Subjects’ Weight Loss while receiving Very Low Calorie Diets consisting of SON, SON-Nutrified Dried Bovine Skim Milk, or Dried Bovine Skim milk provided in the required amounts to achieve Zero Nitrogen Balance. JIMHA; 2:39-48, 1993.
  7. Tamburlin N. L’importanza innovativa nell’uso del MAP per il controllo biologico del peso. La Medicina Biologica; 1:4-10, 1997.
  8. Lucà-Moretti M. Ensayo Comparativo sobre el MAP: el perfil ideal de aminoácidos esenciales para la nutrición humana, International Journal for Biomedical Research and Therapy; 4:9-14, 1997.
  9. Lucà-Moretti M. A Comparative, Double-blind, Triple Crossover Net Nitrogen Utilization Study Confirms the Discovery of the Master Amino Acid Pattern. Annals of the Royal National Academy of Medicine of Spain, Madrid; Vol. CXV: 397-416, 1998.
  10. Lucà-Moretti M. A Comparative, Double-blind, Triple Crossover Net Nitrogen Utilization Study Confirms the Discovery of the Master Amino Acid Pattern. Annals of the Royal Academy of Medicine of Zaragoza. Zaragoza; LXXII, 1998.
  11. Lucà-Moretti M. The International Nutrition Research Center Overweight Management Program. The Library of Congress, USA 1999.
  12. Fidone B. Rettocolite ulcerosa idiopatica: possibilita con MAP (SON Formula). La Medicina Biologica; 3:8-11, 1999.
  13. Sanseverino E. R. Vantaggi dell’utilizzo del MAP in eta’geriatrica. La Medicina Biologica; 3:17-19, 1999.
  14. Lucà-Moretti M. Programma di trattamento e prevenzione della malnutrizione. La Medicina Biologica; 3:35-38, 1999.
  15. Costanzo S. Nuova opportunita nella nutrizione delle popolazioni in situazioni di emergenza. La Medicina Biologica; 3:39-42, 1999.
  16. Mariani E., Vender G., Arrigotti E., Ferrario M., Rovelli E. Variazione di alcuni parametri antropometrici e fisiologici in una marciatrice cinquantenne prima e dopo l’attraversamento in solitaria del deserto cinese. La Medicina Biologica; 3:20-25, 1999.
  17. Tamburlin N. Trattamento ambulatoriale di pazienti con insufficienza renale cronica. La Medicina Biologica; 3:12-16, 1999.
  18. Muratori G. Sovrappeso e patologia articolare: SON Formula come terapia dimagrante ed antalgica un’ipotesi di lavoro. La Medicina Biologica; 17-20, 1999.
  19. Montilla C. Studio comparativo con e senza somministrazione di SON FORMULA® in soggetti affetti da anemia sideropenica sotto trattamento convenzionale. La Medicina Biologica; 3:2-7, 1999.
  20. Riccobene F. Impiego della neuralterapia sec. Huneke in casi di ritensione idrosalina non responsivi alla terapia diuretica in corso di dieta dimagrante con SON Formula. La Medicina Biologica; 3:48-52, 1999.
  21. Hermann G.F. Le intolleranze alimentari. La Medicina Biologica; 3:3-7, 2000.
  22. Corgna M. Pnei e patologie psiconutrizionali in omotossicologia. Il trattamento delle sindromi bulimiche. La Medicina Biologica; 3:8-16, 2000.
  23. Tamburlin N. Il SON Formula come opportunita nella gestione delle intolleranzealimentari. La Medicina Biologica; 3:24-29, 2000.
  24. Di Tullio G. Biotipologia del comportamento alimentare e utilizzo del SON Formula. La Medicina Biologica; 3:34-37, 2000.
  25. Ivaldi G.P. Esperienza nutrizionale in pazienti con insufficienza respiratoria. La Medicina Biologica; 3:49-54, 2000.
  26. Bufalini L. Nutrizione biologica integrata con SON Formula in pazienti affetti da sclerosi multipla. La Medicina Biologica; 3:55-61, 2000.
  27. D’Andrea G. Terapia delle obesitá: Studio comparativo di 10 casi clinici trattati con MAP (Son Formula™) e terapia omotossicologica versus Orlistat (Xenical 120mg Roche). La Medicina Biologica; 3:5-9, 2001.
  28. Di Tullio G. La Malattia asmatica: il ruolo della nutrizione biologica. La Medicina Biologica; 3:15-19, 2001.
  29. Del Prete M. Le malattie infiammatorie intestinali: importanza diagnostica e terapeutica del MAP. La Medicina Biologica; 3:20-26, 2001.
  30. Mariani M.M. Utilizzo del MAP (Master Amino acid Pattern) nel Programma “Quattro D” nell’insufficienza venosa cronica. La Medicina Biologica; 3:33-40, 2001.
  31. Falcone S., Cornoldi A., Brandetti F., Pili M., Badiali M., Spera G., Lubrano C. Integrazione con SON Formula in pazienti grandi obesi operati di by-pass biliointestinale presso il Policlinico Umberto I di Roma. La Medicina Biologica; 3:46-52, 2001.
  32. Fidone B. Nutrizione biologica integrata con SON Formula in pazienti affetti da insufficienza cardiaca. La Medicina Biologica; 3:53-66, 2001.
  33. Bufalini L. Rieducazione nutrizionale e terapia omotossicologica in pazienti anoressiche amenorroiche. La Medicina Biologica; 3:67-71, 2001.
  34. Polito A. Encefalopatia portosistemica in fase terminale in paziente cirrotico: Terapia con SON Formula. La Medicina Biologica; 49-50, 2001.
  35. Tamburlin N. Correlazioni tra micosi cutanuee ed intolleranze alimentari. La Medicina Biologica; 67-75, 2001.
  36. De Cristofano C., Giordano F. Terapia omeopatica integrata in un caso di cirrosi epatica scompensata. La Medicina Biologica; 51-52, 2002.
  37. Lucà-Moretti, M., Grandi A., Lucà E., Mariani E., Vender G., Arrigotti E., Ferrario M., Rovelli E. Comparative Results Between Two Groups of Track and Field Athletes with or without the use of Master Amino Acids Pattern® as protein substitute. Advances in Therapy; 4:195-202, 2003.
  38. Lucà-Moretti, M., Grandi A., Lucà E., Mariani E., Vender G., Arrigotti E., Ferrario M., Rovelli E Results of taking Master Amino Acids Pattern® as a sole and total substitute of dietary proteins in an athlete during a desert crossing. Advances in Therapy; 4:203-210, 2003.
  39. Lucà-Moretti, M., Grandi A., Lucà E., Muratori G., Nofroni M.G., Mucci M.P., Gambetta P., Stimolo R., Drago P., Giudice G., Tamburlin N., Karbalay M., Valente C., Moras G. Master Amino Acids Pattern® as sole and total substitute for dietary proteins during a weight loss diet to achieve the body’s Nitrogen Balance equilibrium. Advances in Therapy; 5:270-281, 2003.
  40. Lucà-Moretti, M., Grandi A., Lucà E., Muratori G., Nofroni M.G., Mucci M.P., Gambetta P., Stimolo R., Drago P., Giudice G., Tamburlin N. Master Amino Acids Pattern® as substitute for dietary proteins during a weight loss diet to achieve the body’s Nitrogen Balance equilibrium with essentially no calories. Advances in Therapy; 5:282-291, 2003.
  41. Ripa S. Il programma SON Formula. Argomenti di medicina estetica biologica; Guna Ed., Milano, 2004.
  42. Marucci S. Linfedema ereditario e malassorbimento proteico con deficit secondario di HGH. La Medicina Biologica; 21-25, 2004.
  43. Turco L. Rete ippocampale come modello della late-life: approccio farmacologico di regolazione nel senex. La Medicina Biologica; 55-59, 2004.
  44. Penco P., Frigerio F., Orlandi S., Molinari R. Progetto SET/K13: Rilievi su un caso estremo. La Medicina Biologica; 15-22, 2006.
  45. Lanza A. Intrauterine Growth Restriction prevention by Master Amino Acid Pattern. Atti del XXI Congresso Nazionale di Omeopatia, Omotossicologia e Medicina Biologica. La Medicina Biologica; 4:35-43, 2006.